Surbhi Sidana, MD

Articles by Surbhi Sidana, MD

Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 22nd 2022

Dr Andrew Cowan describes how the appropriate duration of therapy for patients with transplant-eligible multiple myeloma, and Dr Caitlin Costello discusses her approach to maintenance therapy.

Determining the Right Patients with NDMM for Autologous Stem Cell Transplant

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 22nd 2022

Larry Anderson, MD, explains the study design and outcomes of the DETERMINATION study, and sparks a discussion on which patients with NDMM should receive stem cell transplants.

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Dr Rebecca Silbermann discusses the results of studies evaluating MRD-response adapted therapy in patients with transplant-eligible NDMM.

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

BySurbhi Sidana, MD,Larry Anderson, MD,Caitlin Costello, MD,Andrew J. Cowan, MD,Rebecca Silbermann, MD

September 15th 2022

Surbhi Sidana, MD, and Caitlin Costello, MD, introduce the updated evidence regarding induction regimens for patients with transplant-eligible NDMM and how to select the appropriate induction regimen in this population.

Surbhi Sidana, MD

Articles by Surbhi Sidana, MD

Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM

Determining the Right Patients with NDMM for Autologous Stem Cell Transplant

Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM

Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM

Trending on CancerNetwork

Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer

FDA Accepts BLA for Ivonescimab Regimen in Pretreated EGFR-Mutated NSCLC

New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma

FDA Clears IND for Investigational Program in Recurrent High-Grade Glioma

New Arsenic Trioxide Agent Earns FDA Fast Track Designation in AML Subtype